EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study

Xinyue Li iD, Kaibo Ding, Dujiang Liu, Ruiqi Song, Zhongsheng Peng, Yanjun Xu, Yi Lu

Technology in Cancer Research & Treatment · 2026-05 · 25

DOI: 10.1177/15330338261456203 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 27.05.2026. Verfasst von Xinyue Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang,China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Mutation. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. The optimal treatment strategy after resistance to third-generation EGFR-TKIs still needs further exploration.

Methods

This retrospective study included patients with advanced lung adenocarcinoma who were consecutively enrolled at our hospital between January 2018 and July 2023. All patient data were fully de-identified prior to analysis, and no information that could directly or indirectly identify individual participants was included in this study. We evaluated the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) across various treatment strategies. We also explored the tumor microenvironment (TME) in a subset of patients.

Results

A total of 206 patients were included. Chemo-antiangiogenesis (47.6%) achieved longer mPFS than chemo-immunotherapy (8.00 vs. 5.70 months, p=0.033), with higher ORR (34.7% vs. 16.7%, p=0.003). Median OS was shorter in the immunotherapy group (25.83 vs. 32.33 months, p=0.012). TME analysis (n=27) revealed an immunosuppressive profile (low PD-L1, CCL5, CD8, granzyme B; high Foxp3). In EGFR exon 21 L858R patients, EGFR-TKI continuation was inferior to chemotherapy (mPFS: 3.53 vs. 8.00 months, p=0.001; ORR: 10.5% vs. 40.3%, p=0.015; DCR: 27.4% vs. 69.2%, p=0.009). In oligoprogressive disease, EGFR-TKIs plus radiotherapy improved OS (37.23 vs. 27.77 vs. 25.83 months, p=0.045). Platelet count, LDH, D-dimer, and smoking history were independent predictors of poor prognosis.

Conclusions

Chemo-antiangiogenesis remains a key treatment option after resistance. For oligoprogressive disease, continuing EGFR-TKIs with local radiotherapy may provide superior survival benefit. Chemo-immunotherapy appears less effective, potentially due to an immunosuppressive TME. Prospective validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmMutationProtein Kinase InhibitorsHumansFemaleErbB ReceptorsMaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeTumor MicroenvironmentAdultPrognosisAged, 80 and over

Stichwörter der Autor:innen

antiangiogenic therapyimmunotherapynon-small cell lung cancer (NSCLC)resistancethird-generation EGFR-TKIs

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang,China.
  • Department of Postgraduate Training Base Alliance of Wenzhou Medical University, (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
  • Department of Meizhou People's Hospital (Huangtang Hospital), Guangdong, China.
  • Department of Clinical Nutrition, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

ORCID-Profile: Xinyue Li

Zitieren

APA

Li, X., Ding, K., Liu, D., Song, R., Peng, Z., Xu, Y., & Lu, Y. (2026). Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261456203

Vancouver

Li X, Ding K, Liu D, Song R, Peng Z, Xu Y, et al. Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261456203

BibTeX
@article{Li2026,
  author = {Li, Xinyue and Ding, Kaibo and Liu, Dujiang and Song, Ruiqi and Peng, Zhongsheng and Xu, Yanjun and Lu, Yi},
  title = {Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261456203}
}
Kostenlos starten →